{
    "nct_id": "NCT06462794",
    "official_title": "An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors",
    "inclusion_criteria": "* Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Measurable disease per RECIST v1.1\n* Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue\n* Adequate organ function\n* Additional inclusion criteria may apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated\n* Known active central nervous system (CNS) involvement by malignancy\n* Prior immunotherapy discontinued due to grade 3 or higher immune related adverse event\n* Systemic anticancer treatment within 4 weeks or 5 half lives prior to first dose of study treatment\n* Investigational drug or device within 4 weeks prior to first dose of study treatment\n* Radiation within 2 weeks prior to first dose of study treatment\n* Serious concurrent illness\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply",
    "miscellaneous_criteria": ""
}